基于多参数CT成像的食管癌新辅助放化疗病理反应预测

doi:10.3760/cma.j.cn113030-20201116-00555

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To establish a radiomics-based biomarker for predicting pathological response after preoperative neoadjuvant chemoradiotherapy (nCRT) in locally advanced esophageal cancer. Methods From 2008 to 2018,112 patients with locally advanced esophageal cancer who received nCRT were enrolled. All patients were treated with preoperative nCRT combined with surgery. Enhanced CT images and clinical information before nCRT were collected. A lesion volume of interest was manually delineated. In total, 670 radiomics features (including tumor intensity, shape and size, texture and wavelet characteristics) were extracted using the pyradiomics package in PYTHON. The stepwise regression combined with the best subset were employed to select the features, and finally the Logistic regression model was adopted to establish the prediction model. The performance of the classifier was evaluated by the area under the ROC curve (AUC). Results The pathological complete remission (pCR) rate was 58.0%(65/112). 10 radiomics features were included in the final model, The most relevant radiomics feature was the gray feature (the texture information of the image), followed by the shape and voxel intensity-related features. In the training set, the AUC was 0.750 with a sensitivity of 0.711 and a specificity of 0.778, the corresponding values in the testing set were 0.870, 0.757 and 0.900, respectively. Conclusions Models based on radiomics features from CT images can be utilized to predict the pathological response to nCRT in esophageal cancer. As it is efficient, non-invasive and economic model, it could serve as a promising tool for individualized treatment when validated by further prospective trials in the future.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhu Xiang
	Zhu Chaonan
	Zeng Jian
	Sun Xiaojiang
	Lin Qingren
	Fang Jun
	Chen Ming
	Ji Yongling

Key words： Radiomics Esophageal neoplasm/neoadjuvant chemoradiotherapy Pathological response

Received: 16 November 2020

Fund:Basic Public Welfare Research Program of Zhejiang Province (LGF19H160008)

Corresponding Authors: Ji Yongling, Email:jiyl@zjcc.org.cn;Chen Ming, Email:chenming@zjcc.org.cn

Cite this article:

Zhu Xiang,Zhu Chaonan,Zeng Jian et al. Value of CT radiomics for prediction of pathological response to neoadjuvant chemoradiotherapy in esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1019-1024.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20201116-00555 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I10/1019

[1] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8):1941-1953. DOI:10.1002/ijc.31937.
[2] Noordman BJ, Verdam M, Lagarde SM, et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer:results from the randomized cross trial[J]. J Clin Oncol, 2018, 36(3):268-275. DOI:10.1200/JCO.2017.73.7718.
[3] van de Schoot L, Romme EA, van der Sangen MJ, et al. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage Ⅱ and Ⅲ esophageal cancer[J]. Ann Surg Oncol, 2008, 15(1):88-95. DOI:10.1245/s10434-007-9582-6.
[4] Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 80(4):996-1001. DOI:10.1016/j.ijrobp.2010.03.003.
[5] Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis[J]. Ann Oncol, 2009, 20(2):231-238. DOI:10.1093/annonc/mdn622.
[6] Kumar V, Gu Y, Basu S, et al. Radiomics:the process and the challenges[J]. Magn Reson Imag, 2012, 30(9):1234-1248. DOI:10.1016/j.mri.2012.06.010.
[7] Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics:extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48(4):441-446. DOI:10.1016/j.ejca.2011.11.036.
[8] Limkin EJ, Sun R, Dercle L, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology[J]. Ann Oncol, 2017, 28(6):1191-1206. DOI:10.1093/annonc/mdx034.
[9] Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J]. Cancer, 1994. 73(11):2680-2686. DOI:10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c.
[10] Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation[J]. Cancer, 2005, 103(7):1347-1355. DOI:10.1002/cncr.20916.
[11] Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (PR) following preoperative chemoradiation (CRT)[J]. Ann Surg, 2005, 241(5):810-817;discussion 817-820. DOI:10.1097/01.sla.0000161983.82345.85.
[12] Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer[J]. Jpn J Clin Oncol, 2005, 35(6):316-323. DOI:10.1093/jjco/hyi095.
[13] Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer:CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review[J]. Radiology, 2005, 236(3):841-851. DOI:10.1148/radiol.2363041042.
[14] Jones DR, Parker LA Jr, Detterbeck FC, et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy[J]. Cancer, 1999, 85(5):1026-1032. DOI:10.1002/(sici)1097-0142(19990301)85:5<1026::aid-cncr3>3.0.co;2-n.
[15] van Rossum P, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer:a systematic review and meta-analysis[J]. Gastrointest Endosc, 2016, 83(5):866-879. DOI:10.1016/j.gie.2015.11.026.
[16] Noordman BJ, Spaander M, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO):a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI:10.1016/S1470-2045(18)30201-8.
[17] Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project):a propensity-score matched cohort analysis[J]. Lancet Oncol, 2016, 17(2):174-183. DOI:10.1016/S1470-2045(15)00467-2.
[18] Ypsilantis PP, Siddique M, Sohn HM, et al. Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks[J/OL]. PLoS One, 2015, 10(9):e0137036. DOI:10.1371/journal.pone.0137036.
[19] Paul D, Su R, Romain M, et al. Feature selection for outcome prediction in oesophageal cancer using genetic algorithm and random forest classifier[J]. Comput Med Imaging Graph, 2017, 60:42-49. DOI:10.1016/j.compmedimag.2016.12.002.
[20] Foley KG, Shi Z, Whybra P, et al. External validation of a prognostic model incorporating quantitative PET image features in oesophageal cancer[J]. Radiother Oncol, 2019, 133:205-212. DOI:10.1016/j.radonc.2018.10.033.
[21] Yip C, Davnall F, Kozarski R, et al. Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer[J]. Dis Esophagus, 2015, 28(2):172-179. DOI:10.1111/dote.12170.
[22] Yang Z, He B, Zhuang X, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy[J]. J Radiat Res, 2019, 60(4):538-545. DOI:10.1093/jrr/rrz027.
[23] Chang F, Deere H, Mahadeva U, et al. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy:practical guidelines and current issues[J]. Am J Clin Pathol, 2008, 129(2):252-262. DOI:10.1309/CCR3QN4874YJDJJ7.
[24] Karlo CA, Di Paolo PL, Chaim J, et al. Radiogenomics of clear cell renal cell carcinoma:associations between CT imaging features and mutations[J]. Radiology, 2014, 270(2):464-471. DOI:10.1148/radiol.13130663.
[25] Mazurowski MA. Radiogenomics:what it is and why it is important[J]. J Am Coll Radiol, 2015, 12(8):862-866. DOI:10.1016/j.jacr.2015.04.019.